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Abstract
Background—There have been inconsistent reports of decreased vaccine effectiveness (VE) 
against influenza viruses among older adults (aged ≥65 years) compared with younger adults in 
the United States. A direct comparison of VE over multiple seasons is needed to assess the 
consistency of these observations.
Methods—We performed a pooled analysis of VE over 5 seasons among adults aged ≥18 years 
who were systematically enrolled in the U.S. Flu VE Network. Outpatients with medically-
attended acute respiratory illness (cough with illness onset ≤7 days prior to enrollment) were 
tested for influenza by reverse transcription polymerase chain reaction. We compared differences 
in VE and vaccine failures among older adult age group (65–74, ≥75, and ≥65 years) to adults 
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aged 18–49 years by influenza type and subtype using interaction terms to test for statistical 
significance and stratified by prior season vaccination status.
Results—Analysis included 20,022 adults aged ≥18 years enrolled during the 2011–12 through 
2015–16 influenza seasons; 4,785 (24%) tested positive for influenza. VE among patients aged 
≥65 years was not significantly lower than VE among patients aged 18–49 years against any 
subtype with no significant interaction of age and vaccination. VE against A(H3N2) viruses was 
14% (95% confidence interval [CI]−14% to 36%) for adults ≥65 years and 21% (CI 9%-32%) for 
adults 18–49 years. VE against A(H1N1)pdm09 was 49% (95% CI 22%-66%) for adults ≥65 
years and 48% (95% CI 41%-54%) for adults 18–49 years and against B viruses was 62% (95% 
CI 44%–74%) for adults ≥65 years and 55% (95% CI 45%-63%) for adults 18–49 years. There 
was no significant interaction of age and vaccination for separate strata of prior vaccination status.
Conclusions—Over 5 seasons, influenza vaccination provided similar levels of protection 
among older and younger adults, with lower levels of protection against influenza A(H3N2) in all 
ages.
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INTRODUCTION
Older adults (aged ≥65 years) are at high risk for complications from influenza, including 
hospitalization and death [1–3]. During 2010–2013, older adults comprised 54–70% of 
influenza-associated hospitalizations and 73–85% of influenza-associated deaths in the 
United States [4]. Influenza vaccination is the primary method of prevention of infection and 
has been recommended for all adults aged ≥65 years since the 1960s [5, 6]. Understanding 
factors that contribute to differences in vaccine effectiveness (VE) by age and achieving the 
highest possible VE is a priority, especially for this at-risk group.
The U.S. Flu VE Network publishes estimates of influenza VE each season [7–11], 
including VE by age group. VE has been lower in older adults compared with younger 
adults in some seasons [7, 8, 10], but not others [9, 12]. A prior pooled estimate of U.S. Flu 
VE Network data examining intra-season waning of VE did not find statistical differences in 
VE among adults aged <60 and ≥60 years [13]. A recent meta-analysis has shown that 
although the vaccine is generally effective in adults aged ≥65 years, VE was often lower as 
compared with younger adults, particularly in seasons when A(H3N2) was the predominant 
circulating virus [14].
Most of these prior studies have only assessed VE in single seasons, or in single large age 
groups. We hypothesized that the effectiveness of standard dose inactivated influenza 
vaccines would be lower among older adults compared with younger adults. We pooled 5 
seasons of data from the U.S. Flu VE Network to describe and compare VE among adults 
aged ≥65 years with adults aged 18–49 years.
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MATERIALS AND METHODS
US Flu VE Network
We used data from sites participating in the U.S. Flu VE Network Study [7–9, 11] from the 
2011–12 through 2015–16 influenza seasons. The network enrolled patients aged ≥6 months 
who presented to outpatient providers for an acute respiratory illness (ARI) of ≤7 days 
duration with cough (or fever/feverishness in the 2011–12 season) during periods of local 
influenza circulation across five sites. Interviews were performed at enrollment to collect 
demographic data and self-reported current health status. Oral and nasal swab specimens 
were collected and tested for influenza by reverse transcription polymerase chain reaction 
(RT-PCR) [7]. Patients with inconclusive RT-PCR results and those with two influenza 
viruses detected were excluded. Patients were considered to have high-risk medical 
conditions [15] based on ICD-9 or ICD-10 codes corresponding to a high-risk condition in 
the electronic medical record in the year before enrollment. At selected sites, patients 
without vaccination documented in the medical record or vaccine registry were considered 
vaccinated if plausible date and location of vaccination were provided by self-report. Receipt 
of prior season vaccination was obtained only from medical records or state immunization 
information systems. Patients who received influenza vaccines other than standard dose 
inactivated vaccines were excluded. We limited this analysis to enrolled patients aged ≥18 
years.
Vaccine effectiveness analysis
As reported in previous VE reports by the U.S. Flu VE Network [7–11], we assessed VE 
using the test-negative case-control design [16, 17], with cases defined as patients with lab-
confirmed influenza and controls as patients testing negative for influenza. We calculated the 
odds of vaccination among influenza-positive cases compared to influenza-negative controls 
(OR), and VE was calculated as [1-OR] × 100%. The logistic regression model was adjusted 
for network site, age, sex, race/ethnicity, presence of any high-risk medical condition, self-
rated general health status (excellent, very good, good, fair, poor), interval between illness 
onset and specimen collection (0–2 days, 3–4 days, or 5–7 days), month of illness onset, and 
season. Variables included in the model were decided a priori to compare with prior US Flu 
VE Network estimates. Within each age category, age in months was modeled using linear 
tail-restricted cubic spline functions with multiple knots, as previously described [8, 9].
To test the hypothesis that adults aged ≥65 years had lower VE than adults aged 18–49 
years, we used an interaction term for age group and vaccination for each model. We 
compared VE among adults aged 50–64 years, 65–74 years, ≥75 years, as well as combined 
≥65 years, with the reference group of adults aged 18–49 years. Given wide variations in VE 
by type and subtype [7–11] we conducted analyses by influenza type and subtype. Influenza 
A categories included A(H1N1)pdm09 viruses, which predominated during the 2013–14 and 
2015–16 seasons, and A(H3N2) viruses which predominated during the 2011–12, 2012–13, 
and 2014–15 seasons. Influenza B lineages were combined into a single influenza B 
category due to small numbers. We performed a secondary analysis for A(H3N2) viruses 
removing the 2014–15 season, when the majority of circulating A(H3N2) viruses were 
antigenically different than the viruses in the seasonal vaccines. For comparison with 
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previous studies, additional sensitivity analyses included use of adults aged 50–64 years as 
the referent group and analysis for VE against A(H3N2) viruses restricted to patients with 
influenza-like illness (ARI and fever) and to those with documented vaccination status only.
Given prior reports of repeated vaccination being associated with lower VE [18–20] and the 
fact that the older age groups have consistently higher vaccination rates [21], we tested for a 
significant difference in VE by age group in stratified models by current season and 
immediate prior season vaccination status (vaccinated in both current and prior season vs. 
unvaccinated in both seasons, and vaccinated in current season only vs. unvaccinated in both 
seasons) for influenza A(H3N2).
We also hypothesized that if VE was lower among older adults, the relative odds of vaccine 
failure among enrolled vaccinated patients would be higher compared with adults aged 18–
49 years. To directly compare vaccinated older and younger adults, we performed a post-hoc 
analysis limited to individuals vaccinated in the current season. Using the same covariates, 
we calculated the adjusted OR of influenza among vaccinated adults aged 65–74 years, ≥75 
years and ≥65 years, each compared to vaccinated adults aged 18–49 years as a referent 
group in separate models.
Statistical analyses were conducted using SAS 9.3 (SAS Institute, Cary, NC). We tested for 
significant difference in VE by age group using a p value <0.05 for the age-vaccination 
interaction term.
RESULTS
Patient characteristics
From the 2011–12 through 2015–16 influenza season, the U.S. Flu VE Network enrolled 
20,907 outpatients aged ≥18 years. A total of 885 were excluded from the analyses because 
of receipt of vaccine <14 days prior to illness onset or unknown date or location of self-
reported vaccination (n=385), receipt of high-dose influenza vaccine (n=296) or live 
attenuated influenza vaccine (n=126), inconclusive RT-PCR results (n=47), illness onset >7 
days prior to enrollment (n=30), and co-detection of influenza A and B viruses (n=1). Of the 
remaining 20,022 patients included in the analysis, 56% were aged 18–49 years, 27% were 
aged 50–64 years, 11% were aged 65–74 years, and 6% were aged ≥75 years (Table 1).
Compared with adults aged 18–49 years, adults aged ≥65 years were more likely to have at 
least one high risk condition (74% vs. 27%) and report fair or poor health status (22% vs. 
13%). They also tended to seek care later in illness (5–7 days after symptom onset). Current 
season vaccination was more common in adults aged ≥65 years than aged 18–49 years (79% 
vs 40%). Of those who were vaccinated in the current season and had records available from 
the previous season (n=8,658), 71% were also vaccinated in the prior season and this was 
highest for older adults (86% of adults aged ≥65 years vs. 60% of adults aged 18–49 years).
Overall, 15,237 (76%) tested negative for influenza and 4,785 (24%) tested positive for 
influenza, including 2,265 (47%) influenza A(H3N2), 1,438 (30%) influenza 
A(H1N1)pdm09, 89 (2%) influenza A unsubtyped, 246 (5%) influenza B Victoria lineage, 
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719 (15%) influenza B Yamagata lineage, and 28 (1%) influenza B undetermined lineage. 
The distribution of type and subtype of influenza were similar by age categories but varied 
by season (Table 1).
VE by subtype
Over 5 seasons, VE against influenza A(H1N1)pdm09 was 48% for adults aged 18–49 years 
(CI 38%-57%), 40% (CI 4%-63%) for adults aged 65–74 years, 78% (CI 39%-92%) for 
adults aged ≥75 years, and 49% (CI 22%-66%) for the combined group of adults aged ≥65 
years (Figure 1, Supplemental Table 1). Differences in VE between older adult age groups 
and adults aged 18–49 years were not significant (p values for interaction >0.05) (Figure 1).
For influenza B viruses, VE was 55% for adults aged 18–49 years (CI 45%-63%), 58% (CI 
34%-73%) for adults aged 65–74 years, 77% (40%-91%) for adults aged ≥75 years, and 
62% (CI 44%-74%) for adults aged ≥65 years. Differences in VE between older adult age 
groups and adults aged 18–49 years were not significant (p values >0.05).
Against influenza A(H3N2) viruses, VE was 21% for adults aged 18–49 years (CI 
9.4%-32%), 7.0% (CI−33% to 35%) for adults aged 65–74 years, 23% (CI −26% to 53%) 
for adults aged ≥75 years, and 14% (CI −14% to 36%) for adults aged ≥65 years. 
Differences in VE between older adult age groups and adults 18–49 years were not 
significant (p values >0.05). In subgroup analysis excluding the 2014–15 season, VE against 
A(H3N2) viruses was 35% for adults aged 18–49 years (CI 22%-46%), 10% (CI −51% to 
46%) for adults 65–74 years, 33% (−43% to 68%) for adults aged ≥75 years, and 17% (CI 
−26% to 45%) for adults aged ≥65 years. Again, p values for the interaction terms were not 
significant for any of the older adult age groups.
Given lower VE against A(H3N2) compared to other subtypes, we also examined 
differences in VE against A(H3N2) viruses (excluding the 2014–15 season) by age group 
and prior vaccination status. Among patients with at least one previous year of available 
medical records (N=16,344), 6,163 (38%) had received influenza vaccine in both seasons 
and 2,495 (15%) had received vaccine in the current season only. The percentage who had 
received vaccine in both seasons increased with increasing age (25% of those aged 18–49 
years, 44% 50–64 years, 63% 65–74 years and 75% ≥75 years). VE against A(H3N2) 
viruses (excluding the 2014–15 season) among those who had received vaccine in both 
current and prior seasons was 39% (CI 19%-54%) for adults aged 18–49 years and 1% (CI
−77% to 45%) for adults aged ≥65 years (Table 2). VE against A(H3N2 viruses) (excluding 
the 2014–15 season) among those who had received the current season vaccine but were not 
vaccinated in the prior season was 42% (CI 21%-57%) for adults aged 18–49 years and 14% 
(CI−74% to 58%)) for adults aged ≥65 years (Table 2). P values for interaction terms were 
not significant (p>0.05).
Relative odds of influenza among vaccinated persons
The relative odds of influenza among vaccinated persons varied with type and subtype, and 
age group (Table 3). Relative odds of influenza A(H1N1)pdm09 were lower in the oldest 
adults aged ≥75 years (aOR 0.4, p<0.01) and the combined age group of adults aged ≥65 
years (aOR 0.7, p=0.01) compared with young adults but not for adults aged 65–74 years. 
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Relative odds of influenza B were slightly higher in adults aged 50–64 (aOR 1.4, p=0.01) 
compared with adults aged 18–49 years but were not significantly different for older groups. 
Vaccinated older adults had greater relative odds of having influenza A(H3N2) compared 
with vaccinated adults aged 18–49 years (65–74 years: aOR 1.7, p<0.01, ≥75 years: aOR 
2.1, p<0.01, ≥65 years: aOR 1.9, p<0.01). Results were similar in analyses excluding the 
2014–15 season.
Sensitivity analyses of VE by age group
The interaction between age and vaccination was not significant for older adult age groups 
compared with adults aged 18–49 years in analysis limited to those with fever in addition to 
ARI, a more specific but less sensitive marker for influenza-like illness or when limited to 
persons with documented vaccination history only (Supplemental Table 2).
In a sensitivity analysis using adults aged 50–64 years as the referent group, interaction 
between age and vaccination was not significant for A(H1N1) or B viruses for any groups 
(Supplemental table 3). For A(H3N2), the interaction for age and vaccination was significant 
(overall and excluding the 2014–15 season) in adults aged 65–74 years vs. 50–64 years 
(p=0.04 and 0.03) and the combined age group of adults ≥65 years vs. 50–64 years(p=0.05 
and 0.02), but not for adults aged ≥75 years for (p=0.52 and 0.36).
DISCUSSION
Combining 5 seasons from the U.S. Flu VE Network, we found comparable estimates in 
most analyses of influenza vaccine effectiveness among older and younger adult patients 
presenting with acute respiratory illness for outpatient care. We found no consistent pattern 
of lower vaccine effectiveness among any of the older adult age groupings (65–74 years, ≥75 
years, or ≥65 years) compared with younger adults. For A(H1N1)pdm09 and influenza B 
viruses, there was no statistically significant effect modification comparing older age groups 
to younger adults. For A(H3N2) viruses, VE was not significant for any age group ≥65 years 
whereas VE was significant among adults aged 18–49 and 50–64 years. However, there were 
no statistically significant differences in VE between the older age groups and adults aged 
18–49 years. In addition, there was no pattern of decreasing VE among the oldest adults 
aged ≥75 years as compared with adults aged 65–74 years.
While this analysis suggests that VE against influenza in ambulatory settings is not 
statistically lower in older age groups compared to adults aged 18–49 years, evidence from 
immunogenicity studies show decreased immune response among older adults [22–24]. This 
is thought to be due to immunosenescence, a gradual decline in immune function with age 
including decreased antibody response following immunization and greater reliance on T-
cell mediated response [25]. Multiple serologic studies have found lower immune response 
to standard dose influenza vaccination in older adults compared with younger adults [22, 
23]. In addition to this decreased initial immune response, waning of antibody response and 
VE over the course of a single season has been reported to be more pronounced in the 
elderly [26, 27], though this has not been seen consistently [13]. Despite lower antibody 
levels, those produced may still be enough to provide clinical protection against influenza 
virus infection. In addition, antibodies from prior years may provide residual protection, and 
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there is a possibility of seroprotection despite each subsequent vaccination leading to smaller 
boosts of antibody levels. The effects of prior vaccination vs. immunosenescence are 
difficult to distinguish since older adults have the highest vaccination rates. With low 
numbers of unvaccinated older adults over multiple seasons, we have low power to assess for 
the effects of prior vaccination within this age group [28]. Adjuvanted vaccines lead to 
greater immune response in clinical trials and have recently been licensed in the United 
States for persons aged ≥65 years [22, 23]. Serologic studies have suggested higher immune 
response of older adults to high-dose influenza vaccination [24, 25] and one randomized 
controlled trial has found higher relative effectiveness of high-dose vaccine compared with 
standard [29]. We were not able to assess VE of high-dose influenza vaccine here, and more 
information on VE is needed for these newer, more immunogenic vaccines (high-dose and 
adjuvanted).
Our findings concur with VE estimates published for 2013–14, an A(H1N1)pdm09-
predominant season [9]. Differences in the other yearly VE estimates from the U.S. Flu VE 
Network may be due to the use of documented vaccination only [7, 8] or to our use of a 
reference group, adults aged 18–49 years. Our findings also support those of a recent meta-
analyses of multiple test-negative design case-control studies that found that seasonal 
influenza vaccination was effective against laboratory confirmed influenza in elderly adults 
seeking care in ambulatory settings [33] and found no difference in VE among older adults 
(≥60 years) and younger adults (<60 years) [12].
We set our reference group to be adults aged 18–49 years a priori with the intent to assess 
differences in VE among a wide age range, however, occasionally VE is lower in those aged 
18–49 years compared with those aged 50–64 years [7, 8, 10]. Results in our analysis were 
similar using 50–64 years as a reference group, although we did detect significant effect 
modification of age on VE against influenza A(H3N2) viruses in adults aged 65–74 years 
and ≥65 years vs. 50–64 year olds.
We did not find differences in interactions between age and vaccine effect when stratifying 
by prior vaccination. Although influenza vaccination has been recommended for all persons 
aged ≥6 months since 2010, adults aged ≥65 years were one of the first groups for which 
annual vaccination was recommended and this group has consistently had the highest annual 
immunization rates in the United States [34, 35]. Data from recent observational studies 
suggests possible lower VE point estimates in individuals after repeated vaccination during 
some seasons [36, 37]. We would expect this effect to be most pronounced in the highly 
vaccinated population of older adults.
We hypothesized that with non-statistically significant differences in VE, we would find a 
similar proportion of vaccine-failures in each age group. This was the case for all influenza 
subtypes, except for influenza A(H3N2) viruses, where we found increased relative odds of 
vaccine failure among older adults compared with younger adults. Interaction terms, such as 
we used to calculate VE by age group, generally have lower power and an analysis of 
vaccine-failures by age group, such as we used to calculate the relative odds of vaccine 
failure, has more power to detect differences by age group. The higher relative odds of 
vaccine failure in older adults suggests that VE against A(H3N2) is lower even though the 
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interaction terms were not significant in the VE models. However, these results should be 
interpreted with caution, as there may be differences in exposure, and therefore risk of 
influenza, by age group [38]. The proportion of influenza positive cases may also reflect 
disease severity and care-seeking behaviors that differ by age [39].
Our analysis was subject to several limitations. We relied on interaction terms of age and 
vaccination to assess for effect modification by age, however we may have been limited to 
detect a true effect due to small sample sizes in some strata and seasons. Older adults have 
high and consistent vaccination coverage across multiple years, which limits the size of the 
unvaccinated groups. Unvaccinated older adults are likely different in unmeasured ways 
compared with the majority who are vaccinated annually. The test-negative design has been 
frequently used to assess VE, but may be subject to residual confounding [16, 40] and 
potential biases, which may underestimate the true VE [41]. In addition, vaccination history 
included plausible self-report as well as documentation of vaccination, which may lead to 
misclassification. Vaccines may be given in nontraditional settings, making documentation 
more difficult to obtain. We included those with a plausible self-report of vaccination and 
performed a sensitivity analysis limiting to only individuals with documented vaccination 
history and found similar results consistent with previous studies [7]. We excluded 
individuals who received high-dose vaccination, as we did not have enough sample size to 
compare VE for high-dose to standard dose. The pooled nature of the analysis may be 
weighted towards seasons with higher sample size; however, the percentage of sample size 
comprised of each age group was relatively stable by season. The U.S. Flu VE Network only 
examines VE against medically-attended illness among outpatients and VE may differ when 
examining community illness or influenza-associated hospitalizations or among 
institutionalized persons or persons receiving care in subspecialty clinics. The results of this 
analysis may not be generalizable to those with more severe illness.
Conclusions
We found that over five influenza seasons, influenza vaccination provided similar levels of 
protection among older and younger adults for most seasons across influenza type and 
subtype. Influenza vaccination may have provided less protection against A(H3N2) among 
older adults compared with younger adults as evidenced by the higher relative odds of 
influenza among vaccinated older adults. We found no consistent pattern of lower VE with 
increasing age and did not detect significant modification of VE by age group. Further, we 
did not observe lower VE of standard dose inactivated influenza vaccine among the oldest 
adults (aged ≥75 years). Improving effectiveness of influenza vaccines for adults aged ≥65 
years and younger age groups remains a priority.
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Figure 1. 
Adjusted standard dose inactivated influenza vaccine effectiveness (VE) by influenza type 
and subtype. VE has been adjusted for U.S. Flu VE Network site, age (by month spline), 
sex, race/ethnicity, high-risk health status, self-rated general health status, interval between 
illness onset and specimen collection, season and month of illness onset.
* Referent group and p-value for test of difference in VE in older age group compared with 
VE among adults aged 18–49 years using interaction terms.
† p value for the interaction term of age and vaccination (for the test of significance of the 
interaction term) in model using adults aged 18-49 years as the comparison group.
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